Ketamine One (NEO:MEDI.AQN) Capital Ltd has announced that its wholly-owned contract research organization, KGK Science Inc, has become the first founding sponsor of the Psychedelic Science 2023 event.
The Vancouver, British Columbia-based company said that the event, scheduled for June 19-25, 2023 in Denver, Colorado with an estimated 10,000 attendees, will be the world’s largest gathering of the psychedelic ecosystem.
The event will be hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and is being organized by Momentum Events, the company said.
READ: Ketamine One reports strong 1Q results following transition to medical clinics consolidator
Ketamine One (NEO:MEDI.AQN) said that the Psychedelic Science 2023 will feature three days of panels, workshops, and lectures featuring leaders and visionaries from psychedelic research, education, policy, business, culture, and communities. Conference tracks will be complemented by pre and post-conference workshops, an exhibit hall, and a marketplace featuring artists, musicians, and other vendors from around the world.
Attendees will include MAPS members, donors, researchers, students, clinicians, advocates, therapists, political leaders, entrepreneurs, executives, investors, psychedelic enthusiasts, and those who may benefit from MAPS’ decades of research and advocacy, the company said.
Moreover, Ketamine One (NEO:MEDI.AQN) has granted 200,000 stock options to a director of the company, 1,901,402 restricted share units to arm’s length advisors, and 150,000 common share purchase warrants to consultants to the company.
Each option is exercisable to purchase one common share of the company at a price of $0.27 per share for a period of five years from the date of grant, in accordance with the company’s stock option plan.
Ketamine One is focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments.
Contact Ritika at ritika@proactiveinvestors.com